Related Experiment Video
Updated: Jun 8, 2026
09:44
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Abnormal liver panel in acute kawasaki disease
Mohammed Eladawy1, Samuel R Dominguez, Marsha S Anderson
1Department of Pediatrics, Ain-Shams University School of Medicine, Cairo, Egypt.
The Pediatric Infectious Disease Journal
|September 24, 2010
Summary
Abnormal liver function tests (LFTs) are common in Kawasaki disease (KD). Children with abnormal LFTs present earlier and face a higher risk of resistance to intravenous immunoglobulin (IVIG) treatment.
Area of Science:
- Pediatrics
- Immunology
- Gastroenterology
Background:
- Liver function test (LFT) abnormalities are frequently observed in patients diagnosed with Kawasaki disease (KD).
- Understanding the range of LFT abnormalities and their clinical implications in KD is crucial for patient management.
Purpose of the Study:
- To define the spectrum of liver panel abnormalities in children with Kawasaki disease.
- To investigate the characteristics of KD patients with abnormal LFTs and their treatment response.
Main Methods:
- Retrospective review of medical records for Kawasaki disease patients (2004-2009).
- Comparison of patients with normal LFTs versus those with at least one abnormal LFT (including ALT, AST, GGT, bilirubin).
Main Results:
- Of 259 KD patients, 240 had LFTs performed; 109 (45.4%) showed abnormalities.
- Patients with abnormal LFTs presented earlier and had a higher likelihood of intravenous immunoglobulin (IVIG) resistance.
- No significant difference in coronary artery abnormalities or aneurysms between groups.
- C-reactive protein and total bilirubin at admission predicted IVIG resistance.
Conclusions:
- This study represents the largest US single-center analysis of LFT abnormalities in acute KD.
- Abnormal LFTs are frequent in acute KD and indicate an increased risk of IVIG resistance.
- Early identification of LFT abnormalities may aid in predicting treatment outcomes in KD.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:29Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Acute Kidney Injury I: Introduction
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
01:29Acute Kidney Injury II: Pathophysiology
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...